Sign up
Log in
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Share
Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • JP Morgan analyst Drew Chamberlain initiated coverage on Argan, Inc. (NYSE:AGX) with a Neutral rating and announced a price target of $220. Argan shares closed at $206.63 on Friday. See how other analysts view this stock.
  • RBC Capital analyst Mike Dahl initiated coverage on QXO, Inc. (NYSE:QXO) with an Outperform rating and announced a price target of $33. QXO shares closed at $21.63 on Friday. See how other analysts view this stock.
  • Barclays initiated coverage on Albertsons Companies, Inc. (NYSE:ACI) with an Underweight rating and announced a price target of $19. Albertsons shares closed at $20.47 on Friday. See how other analysts view this stock.
  • Loop Capital analyst Mark Schappel initiated coverage on Autodesk, Inc. (NASDAQ:ADSK) with a Hold rating and announced a price target of $320. Autodesk shares closed at $297.03 on Friday. See how other analysts view this stock.
  • Truist Securities analyst Danielle Brill initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a Buy rating and announced a price target of $385. Alnylam Pharmaceuticals shares closed at $320.53 on Friday. See how other analysts view this stock.

Considering buying ALNY stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.